Literature DB >> 23296720

In vitro JAK kinase activity and inhibition assays.

Jeffrey J Babon1, James M Murphy.   

Abstract

The discovery that a range of myeloproliferative diseases and leukemias are associated with Janus Kinase (JAK) mutations has highlighted the importance of JAK/STAT signalling in disease and sparked a renewed interest in developing JAK inhibitors. In vitro kinase assays are the most direct and quantitative method to assess mutant forms of JAK for altered enzymatic properties as well as verifying and quantifying the affinity and efficacy of potential inhibitors. Here, we describe protocols for heterologous expression and purification of JAK kinases from insect cells, assays to determine the activity of these purified kinases, and finally inhibition assays to determine the effectiveness of potential inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296720     DOI: 10.1007/978-1-62703-242-1_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

1.  Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.

Authors:  Leila N Varghese; Daniela Ungureanu; Nicholas P D Liau; Samuel N Young; Artem Laktyushin; Henrik Hammaren; Isabelle S Lucet; Nicos A Nicola; Olli Silvennoinen; Jeffrey J Babon; James M Murphy
Journal:  Biochem J       Date:  2014-03-01       Impact factor: 3.857

2.  Direct Activation of Human MLKL by a Select Repertoire of Inositol Phosphate Metabolites.

Authors:  Dan E McNamara; Cole M Dovey; Andrew T Hale; Giovanni Quarato; Christy R Grace; Cristina D Guibao; Jonathan Diep; Amanda Nourse; Casey R Cai; Hong Wu; Ravi C Kalathur; Douglas R Green; John D York; Jan E Carette; Tudor Moldoveanu
Journal:  Cell Chem Biol       Date:  2019-04-25       Impact factor: 8.116

3.  Mitogen-activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells.

Authors:  Gabriella K Brown; Cesar Tovar; Anne A Cooray; Alexandre Kreiss; Jocelyn Darby; James M Murphy; Lynn M Corcoran; Silvana S Bettiol; A Bruce Lyons; Gregory M Woods
Journal:  Immunol Cell Biol       Date:  2016-04-19       Impact factor: 5.126

4.  RIPK1- and RIPK3-induced cell death mode is determined by target availability.

Authors:  W D Cook; D M Moujalled; T J Ralph; P Lock; S N Young; J M Murphy; D L Vaux
Journal:  Cell Death Differ       Date:  2014-06-06       Impact factor: 15.828

5.  Genome-wide binding and mechanistic analyses of Smchd1-mediated epigenetic regulation.

Authors:  Kelan Chen; Jiang Hu; Darcy L Moore; Ruijie Liu; Sarah A Kessans; Kelsey Breslin; Isabelle S Lucet; Andrew Keniry; Huei San Leong; Clare L Parish; Douglas J Hilton; Richard J L F Lemmers; Silvère M van der Maarel; Peter E Czabotar; Renwick C J Dobson; Matthew E Ritchie; Graham F Kay; James M Murphy; Marnie E Blewitt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-19       Impact factor: 11.205

6.  The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.

Authors:  Claudia Günther; Gui-Wei He; Andreas E Kremer; James M Murphy; Emma J Petrie; Kerstin Amann; Peter Vandenabeele; Andreas Linkermann; Christopher Poremba; Ulrike Schleicher; Christin Dewitz; Stefan Krautwald; Markus F Neurath; Christoph Becker; Stefan Wirtz
Journal:  J Clin Invest       Date:  2016-10-17       Impact factor: 14.808

7.  CIS is a potent checkpoint in NK cell-mediated tumor immunity.

Authors:  Rebecca B Delconte; Tatiana B Kolesnik; Laura F Dagley; Jai Rautela; Wei Shi; Eva M Putz; Kimberley Stannard; Jian-Guo Zhang; Charis Teh; Matt Firth; Takashi Ushiki; Christopher E Andoniou; Mariapia A Degli-Esposti; Phillip P Sharp; Caroline E Sanvitale; Giuseppe Infusini; Nicholas P D Liau; Edmond M Linossi; Christopher J Burns; Sebastian Carotta; Daniel H D Gray; Cyril Seillet; Dana S Hutchinson; Gabrielle T Belz; Andrew I Webb; Warren S Alexander; Shawn S Li; Alex N Bullock; Jeffery J Babon; Mark J Smyth; Sandra E Nicholson; Nicholas D Huntington
Journal:  Nat Immunol       Date:  2016-05-23       Impact factor: 25.606

8.  FSHD2- and BAMS-associated mutations confer opposing effects on SMCHD1 function.

Authors:  Alexandra D Gurzau; Kelan Chen; Shifeng Xue; Weiwen Dai; Isabelle S Lucet; Thanh Thao Nguyen Ly; Bruno Reversade; Marnie E Blewitt; James M Murphy
Journal:  J Biol Chem       Date:  2018-05-10       Impact factor: 5.157

9.  Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.

Authors:  Cesar Tovar; Ruth J Pye; Alexandre Kreiss; Yuanyuan Cheng; Gabriella K Brown; Jocelyn Darby; Roslyn C Malley; Hannah V T Siddle; Karsten Skjødt; Jim Kaufman; Anabel Silva; Adriana Baz Morelli; Anthony T Papenfuss; Lynn M Corcoran; James M Murphy; Martin J Pearse; Katherine Belov; A Bruce Lyons; Gregory M Woods
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

10.  A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties.

Authors:  James M Murphy; Qingwei Zhang; Samuel N Young; Michael L Reese; Fiona P Bailey; Patrick A Eyers; Daniela Ungureanu; Henrik Hammaren; Olli Silvennoinen; Leila N Varghese; Kelan Chen; Anne Tripaydonis; Natalia Jura; Koichi Fukuda; Jun Qin; Zachary Nimchuk; Mary Beth Mudgett; Sabine Elowe; Christine L Gee; Ling Liu; Roger J Daly; Gerard Manning; Jeffrey J Babon; Isabelle S Lucet
Journal:  Biochem J       Date:  2014-01-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.